NEW YORK, March 24, 2014 /PRNewswire/ -- Delcath
Systems, Inc. (NASDAQ: DCTH) is a specialty pharmaceutical and
medical device company mainly focused on the treatment of primary
and metastatic liver cancers.
Liver cancer is the sixth most common cancer in the world with
nearly 780,000 new cases diagnosed each year. It is estimated by
Global Industry Analysts (GIA) that the potential market for liver
cancer worldwide will exceed $2
billion by the year 2015.
Primary liver cancer (hepatocellular carcinoma, or HCC)
originates in the liver or biliary tissue and is usually associated
with hepatitis-B, hepatitis-C, high levels of alcohol consumption,
aflatoxin, cigarette smoking, exposure to industrial pollutants,
etc. Meanwhile, metastatic liver cancer is characterized by
microscopic cancer cell clusters that detach from the primary site
of disease and travel via the blood stream and lymphatic system
into the liver, where they grow into new tumors. In the US, the
latter is the more common type of liver cancer, while the former is
more common in less developed regions of the world where higher
levels of hepatitis-B and hepatitis-C are reported. As such, HCC is
one of the most prevalent and lethal forms of cancer.
A full in-depth analyst report on DCTH that includes risk
factors, industry review, financial position, potential revenues,
review of current business model, competition breakdown, analyst
summary, and recommendation can be viewed by using the following
link at no cost:
http://bit.ly/DCTH-AnalystReport
copy and paste may be required
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Such forward-looking statements by definition involve risks,
uncertainties and other factors, which may cause the actual
results, performance or achievements of mentioned company to be
materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is written and authored by
Michael Maggi, Chartered Financial
Analyst. An outsourced research services provider represented by
Michael Maggi, Chartered Financial
Analyst, provided Small Cap Street, LLC this article or report.
However, we are only human and are prone to make mistakes. If you
notice any errors or omissions, please notify us below. Small Cap
Street, LLC and BrokerBank Securities, Inc. are not entitled to
veto, interfere or alter the articles, documents or report once
created and reviewed by the outsourced research provider
represented by Michael Maggi,
Chartered Financial Analyst. This press release is being issued to
inform shareholder and potential investors.
Note: Small Cap Street, LLC and BrokerBank Securities, Inc. do
not engage in the business of giving price target or buy or sell
recommendations. The above report is not the opinion of Small Cap
Street, LLC and BrokerBank Securities, Inc.
If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at admin@smallcapir.com. For any urgent concerns or inquiries,
please contact us at admin@smallcapir.com.
NO WARRANTY OR LIABILITY ASSUMED
DCTH has not compensated Small Cap Street, LLC, BrokerBank
Securities, Inc, or Michael Maggi,
Chartered Financial Analyst for the creation or dissemination of
this report. Small Cap Street, LLC and BrokerBank Securities, Inc,
is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or
shortcoming. No liability is accepted by Small Cap Street, LLC and
BrokerBank Securities, Inc. whatsoever for any direct, indirect or
consequential loss arising from the use of this document. Small Cap
Street, LLC and BrokerBank Securities, Inc. expressly disclaims any
fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Small Cap Street, LLC and BrokerBank
Securities, Inc. do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
Small Cap Street, LLC is the party responsible for hosting the
full analyst report on smallcapstreet.com. BrokerBank Securities in
the party responsible for issuing the press release and
Michael Maggi, Chartered Financial
Analyst, is the author of research report. Michael Maggi, Chartered Financial Analyst has
been compensated one hundred dollars
for right to disseminate this report. Information in this release
is fact checked and produced on a best efforts basis by
Michael Maggi, Chartered Financial
Analyst.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial
Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.